🆕article in press: ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors @myESMO@ESTRO_RT
https://t.co/ixNmuaZa6G
The FDA has approved vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. @US_FDA#btsm#oncology https://t.co/nEVYVcsHNO
Clinical pharmacist ratios should be preserved to offer reliable patient care 365 days/yr. As clinical pharmacist services shift from beneficial to essential, continuous daily pt care services must be the practice model moving forward. https://t.co/1hLUJJuvXF @ACCP@MitchBPharmD
📢 Excited to share our multi-disciplinary, comprehensive review on CSF-based liquid biopsy in brain tumors, which allowed us to outline a potential roadmap to standardizing research done in this realm and optimize the integration of CSF analysis into routine clinical practice. #liquidbiopsy #braintumors #gliomas @ASCO@JCO_ASCO
https://t.co/8yNETLHrUG
Happening now! @fritzy_k is presenting at HOPA Annual Conference - reviewing “Nuances in neuro-oncology: glioma treatment advances and new diagnostic definitions” @HOPArx#HOPA2024
Please follow along and repost our content to help highlight the success, recruitment efforts, and hard work of our group! #oncopharm#leadership#hoparx#HCIproud